ClinicalTrials.gg

Program

ifinatamab deruxtecan

Also written as “Ifinatamab deruxtecan”, “I-DXd” and “Ifinatamab Deruxtecan”.

In Merck’s pipeline, Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi. Its studies are mostly in Small Cell Lung Carcinoma · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Lung Neoplasms, led by 2 companies.

Furthest: phase 3, since Apr 7, 202516 company-led studies, 16 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck1010 open or runningphase 3since Apr 7, 2025Nov 14, 2019Jun 12, 2027phase 2 · NCT07405151
Daiichi Sankyo66 open or runningphase 3since Jan 2, 2024Oct 17, 2019Apr 30, 2027phase 2 · NCT04145622
  • Named in Merck’s own pipeline as ifinatamab deruxtecan (MK-2400), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Before these, 1 study since Oct 17, 2019.

  1. Nov 14, 2019Merck’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to MerckMerck · NCT04165070 · 450 planned · United States, Canada, Hungary and more
  2. Feb 23, 2022Phase 2 study in Small Cell Lung CarcinomaDaiichi Sankyo · NCT05280470 · 187 enrolled · United States, China, France and more
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. Jan 2, 2024Phase 2 study in Extensive Stage-small Cell Lung CancerDaiichi Sankyo · NCT06362252 · 123 planned · United States, France, Japan and more
  5. Jan 2, 2024Phase 3 study in Small Cell Lung CarcinomaDaiichi Sankyo · NCT06203210 · 540 planned · United States, Australia, Austria and more
  6. Mar 19, 2024Phase 2 study in RecurrenceDaiichi Sankyo · NCT06330064 · 680 planned · United States, Argentina, Australia and more
  7. Oct 10, 2024Phase 3 study in Esophageal Squamous Cell CarcinomaDaiichi Sankyo · NCT06644781 · 510 planned · United States, Belgium, China and more
  8. Jan 13, 20254 phase 2 studiesMerck · NCT06780137, NCT06780111, NCT06780098 and 1 more
  9. Mar 3, 2025Phase 2 study in Prostatic Neoplasms, Castration-ResistantMerck · NCT06863272 · 360 planned · United States, Argentina, Australia and more
  10. Apr 7, 2025Phase 3 study in Prostatic NeoplasmsMerck · NCT06925737 · 1,440 planned · United States, Argentina, Australia and more
  11. Nov 10, 2025Phase 2 study in Small Cell Lung Cancer Extensive StageMerck · NCT07227597 · 170 planned · United States, Argentina, Chile and more
  12. Feb 5, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaMerck · NCT07405151 · 60 planned · United States, Brazil, Chile and more
  13. Jun 1, 2026Phase 2 study in NeoplasmsMerck · NCT07630974 · 134 planned · United States, Australia, Belgium and more
  14. Oct 1, 2026Primary completion moved from 2026-09-30 to 2027-07-20Date moved laterphase 2 · +10 months · NCT06362252
  15. Oct 9, 2026Primary completion moved from 2031-04-01 to 2031-10-01Date moved laterphase 2 · +6 months · NCT06863272

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in NeoplasmsDaiichi Sankyo · NCT04145622
  2. Jun 12, 2027Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaMerck · NCT07405151
  3. Jul 20, 2027Primary completion: phase 2 study in Extensive Stage-small Cell Lung CancerDaiichi Sankyo · NCT06362252
  4. Jan 30, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaDaiichi Sankyo · NCT06203210

TargetBeta

“Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07630974Neoplasms · United States, Australia, Belgium and more2RecruitingMerckAug 17, 2031134
NCT07405151Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingMerckJun 12, 202760
NCT07227597Small Cell Lung Cancer Extensive Stage · United States, Argentina, Chile and more2RecruitingMerckNov 29, 2030170
NCT06925737Prostatic Neoplasms · United States, Argentina, Australia and more3RecruitingMerckJun 26, 20281,440
NCT06863272Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more2RecruitingMerckOct 1, 2031360
NCT06780137Small Cell Lung Carcinoma · United States, Argentina, Australia and more2RecruitingMerckFeb 15, 2029327
NCT06780111Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingMerckJan 4, 2032298
NCT06780098Lung Neoplasms · United States, Chile, China and more2RecruitingMerckMar 2, 2032144
NCT06780085Carcinoma, Non-Small-Cell Lung · United States, Chile, Germany and more2Active, not recruitingMerckMar 12, 203296
NCT06644781Esophageal Squamous Cell Carcinoma · United States, Belgium, China and more3RecruitingDaiichi SankyoJun 1, 2028510
NCT06330064Recurrence · United States, Argentina, Australia and more2RecruitingDaiichi SankyoJul 25, 2028680
NCT06362252Extensive Stage-small Cell Lung Cancer · United States, France, Japan and more2RecruitingDaiichi SankyoJul 20, 2027123
NCT06203210Small Cell Lung Carcinoma · United States, Australia, Austria and more3RecruitingDaiichi SankyoJan 30, 2028540
NCT05280470Small Cell Lung Carcinoma · United States, China, France and more2Active, not recruitingDaiichi SankyoMar 3, 2025187
NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more2RecruitingMerckFeb 13, 2032450
NCT04145622Neoplasms · United States, Japan2Active, not recruitingDaiichi SankyoApr 30, 2027247

How it is read

Names in the registry

  • “Ifinatamab deruxtecan”, 5 entries
  • “I-DXd”, 3 entries
  • “Ifinatamab Deruxtecan”, 3 entries
  • “Ifinatamab Deruxtecan (I-DXd)”, 3 entries
  • “I-DXD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.